How is AI revolutionizing oncology data? Find out in this special 'New Frontiers' episode (aired on Bloomberg) that explores the evolution of AI-powered oncology Data Intelligence with @Larvol. #LARVOL #BloombergTV #NewFrontiers #Tech #Healthcare #Oncology #CancerResearch #Cancer #CancerData #OncologyData | @brunolarvol

Recap of Day 3 of @EHA_Hematology 2026: Top Trials Explore more insights and data from #EHA2026 👉 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @smbenlazar | @VincentRK | @RahulBanerjeeMD | @HadidiSamer | @graham74GC

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer roche.com/media/releases/med… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #CompanionDiagnostic #ProstateCancer

Episode 29 — AI Biostats etc. x.com/i/broadcasts/1YxNrrOaO…

Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer astrazeneca.com/media-centre… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #ProstateCancer | @OncBrothers | @neerajaiims | @DrChoueiri | @montypal | @nataliagandur

Updated DREAMM7 Data from @EHA_Hematology 2026 in R/R MM from @Larvol and Dr. Kamal Saini (@KSainiMD) 👉ascopubs.org/doi/10.1200/JCO… Updated Landscape: clin.larvol.com/landscape/43… Explore more insights and data from #EHA2026 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @RahulBanerjeeMD | @HadidiSamer | @Abdallah81MD | @VincentRK

Updated NX-5948-301 and CaDAnCe-101 Data from @EHA_Hematology 2026 in the 2L R/R CLL from Jacob Plieth (@JacobPlieth) 👉 x.com/JacobPlieth/status/186… Updated Landscape: clin.larvol.com/landscape/37… Explore more insights and data from #EHA2026 👉 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @calliecoombsmd | @TalhaBadarMD | @Papa_Heme | @Mohty_EBMT

FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma fda.gov/drugs/resources-info… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #RenalCellCarcinoma #KidneyCancer | @DrChoueiri | @tompowles1 | @katy_beckermann | @OncBrothers | @montypal

Updated ANTLER data from @EHA_Hematology 2026 in R/R DLBCL from Dr. Lauren Shea, MD 👉 dailynews.ascopubs.org/do/we… Updated Landscape: clin.larvol.com/landscape/38… Explore more insights and data from #EHA2026 👉 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @graham74GC | @tobyeyre82 | @majorajay | @DrRaulCordoba

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS® investors.guardanthealth.com… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #Guardant360CDx #CompanionDiagnostic #HERNEXEOS #NSCLC #LungCancer #LCSM

LARVOL Oncology Podcast | Episode #32 x.com/i/broadcasts/1MJgNNrng…

Looking for your next Oncology Sales & Marketing leadership opportunity? We've compiled a list of current US-based Oncology Sales & Marketing openings from Top 20 pharmaceutical companies spanning multiple therapeutic areas and leadership levels. Download the June 2026 opportunity list with links 👉 drive.google.com/file/d/1Hyk… #LARVOL #CancerResearch #CancerData #Oncology #ClinicalTrials #PharmaCareers #Biopharma #LifeSciences #MarketingLeadership #JobOpportunities

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer ml-eu.globenewswire.com/Reso… Learn more 👉 clin.larvol.com/trial-detail… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #ColonCancer #Tecentriq | @FASinicropeMD | @MyriamChalabi | @OncBrothers | @bavilima | @UGrewalMD

With @EHA_Hematology 2026 upon us, oncologists are weighing in, sharing, discussing, and debating the most anticipated Heme-Onc abstracts ahead of the meeting. We’re tracking these conversations in real-time, analyzing what’s gaining traction across the global oncology community. Here are the Top Trending Abstracts on 𝕏 ahead of EHA 2026. Which abstract are you watching at EHA 2026? Explore more insights and data from #EHA2026 👉 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | Dr. Mike Thompson (@mtmdphd) Discussion threads: Dr. Amer Zeidan (@Dr_AmerZeidan) 👉 x.com/Dr_AmerZeidan/status/2… Dr. Breno Moreno de Gusmão (@morenodegusmao) 👉 x.com/morenodegusmao/status/… Dr. Toru Miyajima (@tom1006001) 👉 x.com/tom1006001/status/2063…

Top Trending Heme-Onc Trials on 𝕏 ahead of @EHA_Hematology 2026 Ranked by views of oncologist posts on clinical trials. Explore more insights and data from #EHA2026 👉 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @majorajay | @Abdallah81MD | @Mohty_EBMT | @bdermanmd | @HiraSMian

Here are key cancer awareness dates and months to note in 2026 across oncology. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerCare #CancerAwarenes #BreastCancer #BCSM #LungCancer #LCSM #GICancer #GICSM #GUCancer #GUCSM #Melanoma #Lymphoma #Leukemia #MultipleMyeloma #HEMSM #MMSM #LEUSM #LYMSM #HeadAndNeckCancer #KindneyCancer #ColorectalCancer #BloodCancer

Here's our list of the Top 30 Oncology Conferences worldwide to help keep track of the major meetings shaping cancer research and clinical practice in 2026. From global congresses to disease-specific meetings, these conferences are where many of the most important trial readouts and discussions happen. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates #OncologyConferences #OncologyInsights #GI26 #GU26 #ASCO26 #EHA26 #AACR26 #ESMO26 #SITC26 #ASH26 #SABCS26 #2026Events #MedicalConferences The conferences: @ASCO | @ASH_hematology | @SABCSSanAntonio | @EHA_Hematology | @myESMO | @sitcancer | @IASLC | @SocietyofHemOnc | @AACR

We're headed to Stockholm 🇸🇪 for @EHA_Hematology 2026, June 11-14. If you are attending, let’s connect! Explore more insights and data from #EHA2026 👉 clin.larvol.com/conference/a… #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #EHA26 #YoungEHA #HemaSphere #EHA #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @Jud_Prz

Ahead of @ASCO 2026, we asked leading AI models to identify the GYN cancer trials most likely to make an impact. We then compared those predictions with engagement on 𝕏 to see where AI expectations aligned with real-world attention. 👉 Strong alignment at the top: Several studies were consistently highlighted across all four AI models: ▶️ RUBY (128K views) ▶️ ROSELLA (20K views) ▶️ CRB-701-01 ▶️ NRG-GY018 Together, they reflect continued focus on immunotherapy in endometrial cancer and growing interest in new treatment options for ovarian and cervical cancers. 👉 Where buzz outpaced AI expectations: → CHIPRO (26K views), highlighting continued interest in new options for platinum-resistant ovarian cancer → MIROVA (18K views), reflecting enthusiasm around FRα-targeted strategies in ovarian cancer → BLUESTAR (6K views), driven by interest in emerging B7-H4-targeted ADCs 👉 Themes that resonated across AI and the community: ▶️ Immunotherapy remains a major focus in endometrial cancer ▶️ ADC development continues to expand across ovarian, cervical, and endometrial cancers ▶️ Platinum-resistant ovarian cancer remains one of the most closely watched settings ▶️ Novel targets including Nectin-4, B7-H4, FRα, NaPi2b, and c-Met are attracting increasing attention 👉 Where AI and the community diverged: AI models tended to prioritize late-stage, practice-changing studies and established immunotherapy programs, while the community also gravitated toward early-phase ADC datasets and emerging targeted therapies with novel mechanisms. Which gynecologic cancer trial from ASCO 2026 generated the most discussion in your network? Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GynecologicOncology #GYNSM #Gynecology | @pedroramirezMD | @leitaomd | @agz_eriksson | @ShannonWestin | @dsmgyo